AVO Aveon Group LP Com USD0.01

Advanced Medical Optics Adds to Its Market-Leading Portfolio of Refractive IOLs With FDA Approval of the ReZoom Multifocal Refractive Lens SANTA ANA, Calif., March 28 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) (NYSE:AVO), a global leader in ophthalmic surgical devices and eye care products, today added to its market-leading portfolio of refractive intraocular lenses (IOLs) with the announcement that the U.S. Food and Drug Administration (FDA) has approved the ReZoom(TM) multifocal refractive IOL for cataract patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO) The ReZoom(TM) IOL is a new design and next generation acrylic three-piece multifocal IOL. The ReZoom(TM) IOL Balanced View Optics(TM) distribute light over five optical zones for enhanced restoration of visual function, providing distance, intermediate and near vision for reduced spectacle dependence. This allows the lens to match its performance characteristics with the lifestyle demands of the patient. "The ReZoom(TM) multifocal lens adds to our portfolio of refractive IOLs that already includes innovative technologies such as the Verisyse(TM) phakic IOL and the Tecnis(R) Multifocal lens, which is currently being evaluated in a clinical trial in the U.S.," said AMO President and CEO Jim Mazzo. "With our expansive portfolio of refractive IOLs, AMO's strategy is to lead in building the burgeoning global refractive marketplace." Both the ReZoom(TM) and Tecnis(R) Multifocal IOLs have CE Mark approval in Europe for treatment of presbyopia. About Advanced Medical Optics (AMO) AMO is a global leader in the development, manufacturing and marketing of ophthalmic surgical and eye care products. The company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include intraocular lenses, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 3,000 worldwide. The company has operations in about 20 countries and markets products in approximately 60 countries. For more information, visit the company's Web site at http://www.amo-inc.com/. Forward-Looking Statements Statements in this press release regarding Mr. Mazzo's statements, new product benefits, and any other statements that refer to AMO's estimated or anticipated future results are forward-looking statements. All forward- looking statements in this press release reflect AMO's current analysis of existing trends and information and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors affecting AMO's businesses, including but not limited to unexpected changes in competitive, regulatory and market conditions, AMO's ability to obtain adequate product supply and product successful collaborative efforts, unexpected litigation or intellectual property issues, and the uncertainties associated with market acceptance of new products. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous financial press releases issued by AMO. AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's 2004 Form 10-K filed in March 2005 include information concerning these and other risk factors. Copies of press releases and additional information about AMO are available at http://www.amo-inc.com/, or you can contact the AMO Investor Relations Department by calling 714-247-8348. Advanced Medical Optics, Inc. Investors: Sheree Aronson (714) 247-8290 Media: Steve Chesterman (714) 247-8711 http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO http://photoarchive.ap.org/ DATASOURCE: Advanced Medical Optics, Inc. CONTACT: Investors, Sheree Aronson, +1-714-247-8290, , or Media, Steve Chesterman, +1-714-247-8711, , both of Advanced Medical Optics, Inc. Web site: http://www.amo-inc.com/

Copyright